Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin
Lindsey H.M. te Brake, Veronique de Jager, Kim Narunsky, Naadira Vanker, Elin M. Svensson, Patrick P.J. Phillips, Stephen H. Gillespie, Norbert Heinrich, Michael Hoelscher, Rodney Dawson, Andreas H. Diacon, Rob E. Aarnoutse, Martin J. Boeree on behalf of the PanACEA Consortium
European Respiratory Journal 2021; DOI: 10.1183/13993003.00955-2020
Lindsey H.M. te Brake
1Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands
Veronique de Jager
2TASK Applied Science, Cape Town, South Africa
Kim Narunsky
3University of Cape Town Lung institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Naadira Vanker
2TASK Applied Science, Cape Town, South Africa
Elin M. Svensson
1Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands
4Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
Patrick P.J. Phillips
5UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, United States
Stephen H. Gillespie
6School of Medicine, University of St Andrews, St Andrews, United Kingdom
Norbert Heinrich
7Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany
8German Center for Infection Research (DZIF), Munich, Germany
Michael Hoelscher
7Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany
8German Center for Infection Research (DZIF), Munich, Germany
Rodney Dawson
3University of Cape Town Lung institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Andreas H. Diacon
2TASK Applied Science, Cape Town, South Africa
Rob E. Aarnoutse
1Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands
Martin J. Boeree
9Department of Lung Diseases, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands
Vol 63 Issue 4
Table of Contents
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin
Lindsey H.M. te Brake, Veronique de Jager, Kim Narunsky, Naadira Vanker, Elin M. Svensson, Patrick P.J. Phillips, Stephen H. Gillespie, Norbert Heinrich, Michael Hoelscher, Rodney Dawson, Andreas H. Diacon, Rob E. Aarnoutse, Martin J. Boeree
European Respiratory Journal Jan 2021, 2000955; DOI: 10.1183/13993003.00955-2020
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin
Lindsey H.M. te Brake, Veronique de Jager, Kim Narunsky, Naadira Vanker, Elin M. Svensson, Patrick P.J. Phillips, Stephen H. Gillespie, Norbert Heinrich, Michael Hoelscher, Rodney Dawson, Andreas H. Diacon, Rob E. Aarnoutse, Martin J. Boeree
European Respiratory Journal Jan 2021, 2000955; DOI: 10.1183/13993003.00955-2020